FDA’s Rosebraugh Says OTC Labeling Studies Should Be More Rigorous
This article was originally published in The Tan Sheet
Executive Summary
OTC drug manufacturers and FDA should collaborate to raise the quality of actual use and label comprehension studies to the level of clinical trials, according to OTC Drug Division Deputy Director Curtis Rosebraugh, MD